These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18571837)

  • 1. Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer.
    Tischkowitz MD; Yilmaz A; Chen LQ; Karyadi DM; Novak D; Kirchhoff T; Hamel N; Tavtigian SV; Kolb S; Bismar TA; Aloyz R; Nelson PS; Hood L; Narod SA; White KA; Ostrander EA; Isaacs WB; Offit K; Cooney KA; Stanford JL; Foulkes WD
    Cancer Lett; 2008 Oct; 270(1):173-80. PubMed ID: 18571837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
    Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
    Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population.
    Shaag A; Walsh T; Renbaum P; Kirchhoff T; Nafa K; Shiovitz S; Mandell JB; Welcsh P; Lee MK; Ellis N; Offit K; Levy-Lahad E; King MC
    Hum Mol Genet; 2005 Feb; 14(4):555-63. PubMed ID: 15649950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-evaluating cancer risks associated with the CHEK2 p.Ser428Phe Ashkenazi Jewish founder pathogenic variant.
    Laitman Y; Nielsen SM; Hatchell KE; Truty R; Bernstein-Molho R; Esplin ED; Friedman E
    Fam Cancer; 2022 Jul; 21(3):305-308. PubMed ID: 34622392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel founder CHEK2 mutation is associated with increased prostate cancer risk.
    Cybulski C; Huzarski T; Górski B; Masojć B; Mierzejewski M; Debniak T; Gliniewicz B; Matyjasik J; Złowocka E; Kurzawski G; Sikorski A; Posmyk M; Szwiec M; Czajka R; Narod SA; Lubiński J
    Cancer Res; 2004 Apr; 64(8):2677-9. PubMed ID: 15087378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women.
    Novak DJ; Chen LQ; Ghadirian P; Hamel N; Zhang P; Rossiny V; Cardinal G; Robidoux A; Tonin PN; Rousseau F; Narod SA; Foulkes WD
    BMC Cancer; 2008 Aug; 8():239. PubMed ID: 18706089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
    Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Clinical and Genetic Analysis of
    Kirchner K; Gamulin M; Kulis T; Sievers B; Kastelan Z; Lessel D
    Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in CHEK2 associated with prostate cancer risk.
    Dong X; Wang L; Taniguchi K; Wang X; Cunningham JM; McDonnell SK; Qian C; Marks AF; Slager SL; Peterson BJ; Smith DI; Cheville JC; Blute ML; Jacobsen SJ; Schaid DJ; Tindall DJ; Thibodeau SN; Liu W
    Am J Hum Genet; 2003 Feb; 72(2):270-80. PubMed ID: 12533788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden.
    Wagenius M; Borg A; Johansson L; Giwercman A; Bratt O
    Scand J Urol Nephrol; 2006; 40(1):23-5. PubMed ID: 16452051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
    JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic architecture of prostate cancer in the Ashkenazi Jewish population.
    Vijai J; Kirchhoff T; Gallagher D; Hamel N; Guha S; Darvasi A; Lencz T; Foulkes WD; Offit K; Klein RJ
    Br J Cancer; 2011 Sep; 105(6):864-9. PubMed ID: 21829199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews.
    Rennert H; Bercovich D; Hubert A; Abeliovich D; Rozovsky U; Bar-Shira A; Soloviov S; Schreiber L; Matzkin H; Rennert G; Kadouri L; Peretz T; Yaron Y; Orr-Urtreger A
    Am J Hum Genet; 2002 Oct; 71(4):981-4. PubMed ID: 12145743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A personalised approach to prostate cancer screening based on genotyping of risk founder alleles.
    Cybulski C; Wokołorczyk D; Kluźniak W; Kashyap A; Gołąb A; Słojewski M; Sikorski A; Puszyński M; Soczawa M; Borkowski T; Borkowski A; Antczak A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Domagała P; Piotrowski K; Menkiszak J; Krzystolik K; Gronwald J; Jakubowska A; Górski B; Dębniak T; Masojć B; Huzarski T; Muir KR; Lophatananon A; Lubiński J; Narod SA;
    Br J Cancer; 2013 Jun; 108(12):2601-9. PubMed ID: 23722471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer.
    Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; Gliniewicz B; Sikorski A; Stawicka M; Godlewski D; Kwias Z; Antczak A; Krajka K; Lauer W; Sosnowski M; Sikorska-Radek P; Bar K; Klijer R; Zdrojowy R; Małkiewicz B; Borkowski A; Borkowski T; Szwiec M; Narod SA; Lubiński J
    J Med Genet; 2006 Nov; 43(11):863-6. PubMed ID: 17085682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of CHEK2 mutations in prostate cancer.
    Wu X; Dong X; Liu W; Chen J
    Hum Mutat; 2006 Aug; 27(8):742-7. PubMed ID: 16835864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system.
    Delimitsou A; Fostira F; Kalfakakou D; Apostolou P; Konstantopoulou I; Kroupis C; Papavassiliou AG; Kleibl Z; Stratikos E; Voutsinas GE; Yannoukakos D
    Hum Mutat; 2019 May; 40(5):631-648. PubMed ID: 30851065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population.
    Foulkes WD; Thiffault I; Gruber SB; Horwitz M; Hamel N; Lee C; Shia J; Markowitz A; Figer A; Friedman E; Farber D; Greenwood CM; Bonner JD; Nafa K; Walsh T; Marcus V; Tomsho L; Gebert J; Macrae FA; Gaff CL; Paillerets BB; Gregersen PK; Weitzel JN; Gordon PH; MacNamara E; King MC; Hampel H; De La Chapelle A; Boyd J; Offit K; Rennert G; Chong G; Ellis NA
    Am J Hum Genet; 2002 Dec; 71(6):1395-412. PubMed ID: 12454801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.
    Schutte M; Seal S; Barfoot R; Meijers-Heijboer H; Wasielewski M; Evans DG; Eccles D; Meijers C; Lohman F; Klijn J; van den Ouweland A; Futreal PA; Nathanson KL; Weber BL; Easton DF; Stratton MR; Rahman N;
    Am J Hum Genet; 2003 Apr; 72(4):1023-8. PubMed ID: 12610780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.